Karman (KRMN) is currently undervalued compared to its aerospace and defense peers despite leading revenue and EBITDA growth. The company reported strong Q1 results and provided robust guidance for 2026, supported by high revenue visibility. Key growth drivers include new munitions acceleration agreements, an expanding Space and Launch pipeline, and a pending $250 million contract. Despite a nearly 31% stock decline this year and risks from a secondary offering and CEO transition, the stock is viewed as a compelling buy with a $70 price target based on 2027 EV/EBITDA multiples.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Citigroup downgraded Apollo Global Management's stock from Buy to Reduce due to concerns over a potential economic slowdown and a sharp drop in U.S. private credit lending. Apollo's shares are trading well below their 52-week high, reflecting caution...
Conagra Brands reported its Q2 earnings with an EPS of $0.47, slightly beating estimates but down from last year. Revenue missed expectations at $2.88 billion, and the company announced a loss and a significant dividend cut as part of a new conservat...
